Price Action To Observe: What’s Ahead for ImmuCell Corporation After Achieving 52-Week Low?

Price Action To Observe: What's Ahead for ImmuCell Corporation After Achieving 52 Week Low?

The stock of ImmuCell Corporation (NASDAQ:ICCC) hit a new 52-week low and has $4.34 target or 14.00% below today’s $5.05 share price. The 9 months bearish chart indicates high risk for the $19.62M company. The 1-year low was reported on Nov, 7 by If the $4.34 price target is reached, the company will be worth $2.75M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 28,605 shares traded hands or 68.73% up from the average. ImmuCell Corporation (NASDAQ:ICCC) has declined 25.51% since April 5, 2016 and is downtrending. It has underperformed by 27.46% the S&P500.

Analysts await ImmuCell Corporation (NASDAQ:ICCC) to report earnings on November, 10.

According to Zacks Investment Research, “ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibody technology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea.”

Insitutional Activity: The institutional sentiment decreased to 1.5 in 2016 Q2. Its down 12.50, from 14 in 2016Q1. The ratio turned negative, as 0 funds sold all ImmuCell Corporation shares owned while 4 reduced positions. 0 funds bought stakes while 6 increased positions. They now own 911,107 shares or 50.10% less from 1.83 million shares in 2016Q1.
Essex Svcs Incorporated has 23,776 shares for 0.04% of their US portfolio. Creative Planning reported 310 shares or 0% of all its holdings. Heartland Advsrs reported 204,972 shares or 0.08% of all its holdings. Walleye Trading Ltd Co holds 15 shares or 0% of its portfolio. Acadian Asset Management Limited Co, a Massachusetts-based fund reported 1,923 shares. Healthinvest, a Sweden-based fund reported 168,323 shares. Morgan Stanley has invested 0% of its portfolio in ImmuCell Corporation (NASDAQ:ICCC). National Bank & Trust Of America Corp De holds 2,032 shares or 0% of its portfolio. Renaissance Tech Ltd Liability Com has 64,200 shares for 0% of their US portfolio. Minerva Advsr Limited Liability Company, a Pennsylvania-based fund reported 14,559 shares. Deutsche Savings Bank Ag owns 1,785 shares or 0% of their US portfolio. Tower Research (Trc) holds 0% or 330 shares in its portfolio. Vanguard Gp last reported 22,875 shares in the company. Shufro Rose Limited last reported 42,191 shares in the company. Wells Fargo And Mn, a California-based fund reported 1,001 shares.

Insider Transactions: Since July 7, 2016, the stock had 1 insider buy, and 2 insider sales for $8,949 net activity. $12,669 worth of ImmuCell Corporation (NASDAQ:ICCC) was sold by CRABB JOSEPH H. Cunningham David bought $21,431 worth of ImmuCell Corporation (NASDAQ:ICCC) on Monday, August 22.

More important recent ImmuCell Corporation (NASDAQ:ICCC) news were published by: which released: “Immucell Corp. ICCC (US: Nasdaq)” on February 11, 2011, also published article titled: “Immucell Corp (ICCC) Offers Prelim. Q3 Results; Says Sales Fell 20%”, published: “ImmuCell Corporation Announces Closing of $3.5 Million Private Placement of …” on October 21, 2016. More interesting news about ImmuCell Corporation (NASDAQ:ICCC) was released by: and their article: “10 Biggest Mid-Day Losers For Tuesday” with publication date: October 18, 2016.

ICCC Company Profile

ImmuCell Corporation, incorporated on February 9, 1987, is an animal health company. The Firm operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Firm has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company’s lead product, First Defense, is manufactured from cows’ colostrum (the milk that a cow produces immediately after giving birth) utilizing its vaccine and milk protein purification technologies. The Company’s Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. The Firm also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. The Company’s product development initiative is Mast Out, a Nisin intramammary treatment of subclinical mastitis in lactating dairy cows.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment